Cardiology

Administration of Interleukin-15 Peptide Improves Cardiac Function in a Mouse Model of Myocardial Infarction.


Icon for Wolters Kluwer Icon for PubMed Central Related Articles

Administration of Interleukin-15 Peptide Improves Cardiac Function in a Mouse Model of Myocardial Infarction.

J Cardiovasc Pharmacol. 2020 01;75(1):98-102

Authors: Ameri K, Bayardorj D, Samurkashian R, Fredkin M, Fuh E, Nguyen V, Yeghiazarians Y

Abstract
Interleukin-15 is a pleotropic factor, capable of modulating metabolism, survival, proliferation, and differentiation in many different cell types. The rationale behind this study relates to previous work demonstrating that IL-15 is a major factor present in stem cell extracts, which protects cardiomyocytes subjected to hypoxic stress in vitro. The objective of this current study was to assess whether administration of IL-15 peptide will also show protective effects in vivo. The data indicate that administration of IL-15 reduces cell death, increases vascularity, decreases scar size, and significantly improves left ventricular ejection fraction in a mouse model of myocardial infarction.

PMID: 31815824 [PubMed – indexed for MEDLINE]

Source link

Related posts

Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial [Original Articles]

Newsemia

Successful transcatheter pulmonary valve implantation in a dog: first clinical report.

Newsemia

cardiology; +350 new citations

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World